2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the recent exciting advancements in the field of multiple myeloma during the American Society of Hematology (ASH) Annual Meeting.
Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the recent exciting advancements in the field of multiple myeloma during the American Society of Hematology (ASH) Annual Meeting.
Last year was a very exciting year for the field of multiple myeloma, Thompson says, with many new drugs approved to treat the disease, including daratumumab (Darzalex). This year is about sorting out how to best use those drugs.
Recent study findings have confirmed the efficacy of daratumumab long-term, which is very exciting, Thompson says. Now, researchers are starting to investigate the drug in combination studies.
Related Content: